US Lung Cancer Drug Pipeline Analysis
The most common type of cancer in terms of incidence and mortality rate is Lung cancer. Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which in turn leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer which accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers. The major cause for around 80% of all lung cancers is the use of tobacco. Other causes include excessive usage of asbestos and high exposure to radon gas.
Lung cancer has emerged as a major cause of deaths among cancer patients in US as compared to other types of cancers. This trend is a common feature among both men and women in the US. According to the most recent annual statistics published, an estimated 201,144 people in the United States were diagnosed with lung cancer. This figure included 107,164 men and 93,980 women. Among the various remedies for cancer, the category of therapeutic drugs is becoming increasingly popular among the pharma companies, and hence these players are attracted towards investing in this area in order to garner the opportunities in the market. Additionally, among all the regions, the US market is expected to grow at a faster rate during the next 4-5 years, which is also another reason for vendors to focus significantly on the US market.
“US Lung Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Lung Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Lung Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Lung Cancer Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 4
- Preclinical: 30
- Clinical: 3
- Phase-I: 26
- Phase-I/II: 18
- Phase-II: 82
- Phase-II/III: 2
- Phase-III: 24
- Registered: 2
- Marketed: 14
- Unknown Phase: 1
2. LUNG CANCER DRUG CLINICAL PHASE: UNKNOWN
2.1 Overview
2.2 Lung Cancer Drug Profile in Clinical Phase
3. LUNG CANCER DRUG CLINICAL PHASE: RESEARCH
3.1 Overview
3.2 Lung Cancer Drug Profile in Clinical Phase
4. LUNG CANCER DRUG CLINICAL PHASE: PRECLINICAL
4.1 Overview
4.2 Lung Cancer Drug Profile in Clinical Phase
5. LUNG CANCER DRUG CLINICAL PHASE: CLINICAL
5.1 Overview
5.2 Lung Cancer Drug Profile in Clinical Phase
6. LUNG CANCER DRUG CLINICAL PHASE: PHASE-I
6.1 Overview
6.2 Lung Cancer Drug Profile in Clinical Phase
7. LUNG CANCER DRUG CLINICAL PHASE: PHASE-I/II
7.1 Overview
7.2 Lung Cancer Drug Profile in Clinical Phase
8. LUNG CANCER DRUG CLINICAL PHASE: PHASE-II
8.1 Overview
8.2 Lung Cancer Drug Profile in Clinical Phase
9. LUNG CANCER DRUG CLINICAL PHASE: PHASE-II/III
9.1 Overview
9.2 Lung Cancer Drug Profile in Clinical Phase
10. LUNG CANCER DRUG CLINICAL PHASE: PHASE-III
10.1 Overview
10.2 Lung Cancer Drug Profile in Clinical Phase
11. LUNG CANCER DRUG CLINICAL PHASE: REGISTERED
11.1 Overview
11.2 Lung Cancer Drug Profile in Clinical Phase
12. MARKETED
12.1 Overview
12.2 Marketed Lung Cancer Drug Profile
Each Drug Profile has Tables Representing Following Information:
- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class
- Mechanism of Action
- ATC Code
- Designated Brand Name
Incidence
In the USA, a major cause of deaths among cancer patients is specifically lung cancer as compared to other types of cancers. This trend is a common feature among both men and women in the US. According to the most recent annual statistics published, an estimated xx people in the United States were diagnosed with lung cancer. This figure included xx men and xx women. Additionally, it was estimated that around xx people died from lung cancer, which included xx men and xx women.
Market Overview
Among the various remedies for cancer, the category of therapeutic drugs is becoming increasingly popular among the pharma companies, and hence these players are attracted towards investing in this area in order to garner the opportunities in the market. Additionally, among all the regions, the US market is expected to grow at a faster rate during the next 4-5 years, which is also another reason for vendors to focus significantly on the US market.
It has been estimated that the U.S. market approximately worth USD xx billion in 2010, dominates the global lung cancer drug market, with a share of xx%. Due to factors such as high rate of smoking, and increasing cancer prevalence, the lung cancer drugs market in the US is expected to grow at around xx-xx% to reach approximately USD xx billion by 2016.
Factors Driving Lung Cancer Market in the US
- Large number of Smokers
- Exposure to Radon
- High occupational exposures
